Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ME2 | P23368 | 1/20 | 0.47 |
| ▸ | ME1 | P48163 | 1/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454329 | 0.85 | KMT2A (0.57) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5458260 | 0.85 | NAMPT (0.61) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5459811 | 0.84 | MEN1 (0.60) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5462047 | 0.83 | HTT (0.57) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5463537 | 0.83 | MAPT (0.59) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5459612 | 0.83 | NPC1 (0.58) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5465394 | 0.82 | RAB9A (0.75) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5460048 | 0.81 | MAPT (0.51) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5458128 | 0.80 | TRPV1 (0.50) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL5465117 | 0.80 | KMT2A (0.61) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | MEN1 1828/4885KMT2A 1350/4885MAPT 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.